×

[Comment] Offline: The message of mental health

One entirely avoidable and indefensible tragedy of the global response to non-communicable diseases has been its extraordinary failure to embrace mental health. Instead, advocates and international institutions, such as WHO, have preferred to emphasise the simple (and simplistic) message of “four-by-four”—four key diseases (heart disease, cancer, diabetes, and chronic respiratory diseases) and four key risk factors (tobacco use, alcohol, unhealthy diets, and physical inactivity). It is not that those who preside over global health today have been ignorant of the mental health crisis befalling our world.

[Comment] Triple therapy for symptomatic patients with COPD

Combination therapy is almost the standard for treating chronic diseases, including chronic obstructive pulmonary disease (COPD).1 Until 2016, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendation for highly symptomatic COPD patients at risk of exacerbations or severe airflow limitation (GOLD D) was treatment with either long-acting muscarinic antagonists (LAMA) or long-acting β2-agonists (LABA) in combination with inhaled glucocorticosteroids (ICS), both with strong evidence.

[Comment] Death, disease, and tobacco

Throughout history, humanity has been blighted by epidemics of communicable diseases that medical science and public policy have, to varying degrees, been able to control. Sanitation, immunisation, mosquito nets, and antimicrobial agents are examples of developments that have helped to generate substantial reductions in incidence of and mortality from cholera, dysentery, smallpox, measles, HIV, tuberculosis, and many other infectious diseases. Similar success is now urgently required to halt the global spread of non-communicable diseases that have dominated health in high-income countries for the past century, and are now emerging as major disease burdens in low-income and middle-income countries.

[Obituary] Alexis Shelokov

Physician scientist specialising in infectious disease. He was born in Harbin, China, on Oct 18, 1919, and died with aplastic anaemia in Dallas, TX, USA, on Dec 16, 2016, aged 97 years.

Immunisations in pharmacies

BY PROFESSOR STEPHEN LEEDER, EMERITUS PROFESSOR PUBLIC HEALTH, UNIVERSITY OF SYDNEY

Controversy swirls around this topic. I sounded out several colleagues, including pharmacists.

 An infectious disease physician: “(I see) no fundamental reason why not … under certain conditions: they keep recipients on site for 15 mins to make sure they do not suffer anaphylaxis; they [are] trained to resuscitate; they record the vaccination and report to the Immunisation Register and to the recipient’s GP and provide the recipient with an appropriate record. It might suit … families lacking access to bulk-billing GPs or who can’t organise appointments.”

An interested physician recognised this contentious issue, mainly because it disrupts GP-patient relationships.

“I’ve never been convinced (by the AMA), especially (regarding) flu vaccine – where adults >65 and parents of school-age children (need) GP appointments at convenient times. Pharmacists are well-equipped for following procedures, including cold-chain logging and record-keeping.” 

Pharmacists recognised the risk of commercial pressures. Some saw pressure from the corporate chains which dominate retail pharmacy. They spoke of decreasing professional satisfaction, rather as can be heard said in general practice about corporatisation.

Westmead Hospital’s chief pharmacist, David Ng, helped set up the first pharmacy program in South Australia. He wrote: “There has been a pharmacy influenza immunisation program in several (American) states since the 1990s. South Australia and Queensland … introduce[d] enabling legislation and training programs several years ago, followed by NSW in 2015. Queensland has extended (these) programs to measles and pertussis.

“This service is underutilised because [there is no] MBS (rebate) and … the need for two pharmacists to be present for one to administer vaccine.

“Large chains … circumvent this by introducing contract GPs or nurse immunisers.

“… the system does not appear ready for a major influenza pandemic!”

An academic perspective

Professor Iqbal Ramzan, Dean of Pharmacy at the University of Sydney, commented: “Falling vaccination rates … pose a public health threat …all health professionals [must) maximise vaccine coverage.

“Most jurisdictions allow pharmacists (with) approved training to provide influenza vaccination. While there may be some disquiet within the medical fraternity, pharmacists have the requisite theoretical knowledge and, with training, the skills required to administer vaccines. Pharmacies offer easy access … this also provides GPs with valuable time to discuss complex issues with their patients.”

To their credit, pharmacists have established sophisticated training and operating procedures. Accreditation is recognised for best practice.

The facts of the matter

A recent paper, Evaluation of the first pharmacist-administered vaccinations in Western Australia: a mixed-methods study,by H Laetitia Hattingh and colleaguesreported on 15,621 influenza vaccinations administered by pharmacists at 76 community pharmacies in 2015.

They found “no major adverse events;  less than 1 per cent of consumers experienced minor events, which were appropriately managed. Between 12 per cent and 17 per cent eligible [for] free influenza vaccinations chose to have it at a pharmacy.

“A high percentage was delivered in rural and regional areas [where] pharmacist vaccination facilitated access. Immuniser pharmacists reported feeling confident … and [felt] that services should be expanded to other vaccinations.”

The authors concluded: “Vaccine delivery was safe. Convenience and accessibility were important. There is scope to expand to other vaccines and younger children; however, government funding needs to be considered.”

This is a work in progress.  While risk is often part of treatment, its acceptability there is because we can see readily that the risk of doing nothing is greater. This is not as clear in relation to prevention where the risk of developing the condition is vague and located somewhere in the future.  But discussions of this sort are an essential part of our national immunisation program’s public acceptability. Whoever does the immunising must be prepared to have it with those being immunised. 

 

 

 

It’s time for a tax on sugary drinks

BY PATRICK WALKER

Soft drinks are fast becoming our nation’s vice; our go-to drink choice that’s more bitter than it is sweet. Sugar-sweetened beverages (SSBs) are packed full of calories, yet provide no additional nutritional value or health benefits, and are a major factor driving obesity in Australia and overseas.

Consider your average 600ml bottle of Coca-Cola – for most people, a single serving. That bottle might cost you $3 from your local supermarket, and contains approximately 64g of sugar.

For the average person, this alone exceeds the WHO recommendation that no more than 10 per cent of your dietary energy should come from free sugars. Not that we’re paying much notice to this recommendation, though – most of us exceed it on a daily basis, and SSBs such as that $3 bottle of coke play a large role in this.

Sugar-sweetened drinks are Australians’ largest source of free sugar intake, perhaps adding flavour and energy to our day, but certainly nothing more. Sugar is only one factor of many that predispose to overweight and obesity, but plays a considerable role that merits attention. A 2006 systematic review, for example, found SSBs to be a ‘key contributor’ to the obesity epidemic, calling for prompt public health strategies to discourage consumption.

In total, 63 per cent of Australians are now overweight or obese, a staggering four-fold increase on 1980 levels. Perhaps more concerning is the fact that one in four children exceed the upper limit of normal for BMI, and many of these kids will continue on to become overweight or obese adults. Most people know that overweight and obesity lead to an increased risk of cardiovascular disease and stroke, diabetes, certain cancers, and a multitude of other diseases. But something that’s often overlooked is their economic toll.

In 2005, data from the Australian Diabetes, Obesity and Lifestyle study put the total direct cost at $21 billion, with the figure ballooning out to $56.6 billion when indirect costs are factored in. Other estimates are more moderate, but the evidence is clear: our waistlines are costing us billions.

Compare that to the $500 million in additional revenue that a well-designed SSB tax could raise annually, as well as bringing about a 15 per cent reduction in SSB consumption and a resulting 2 per cent reduction in the prevalence of obesity.

The link between SSBs and weight gain is well established, as is the link between weight gain and poor outcomes – both health and economic. But where does a tax fit in? And why target SSBs?

Let’s start with the first question. Put simply, price affects consumption. The more things cost, the less likely people are to buy them, particularly products with elastic demand such as SSBs. We saw this with tobacco and alcohol, with increased taxation dramatically reducing consumption. Now is the time to move this strategy to SSBs.

A 2013 meta-analysis on the impact of increased price on SSB consumption found that demand does indeed drop, leading to beneficial health outcomes. Further, the effect is more pronounced for people with low income, due to increased price elasticity. Given these people suffer disproportionately from overweight, obesity, and non-communicable diseases, this means they have the most to gain.

As a discrete and well-defined group of products that provide minimal nutritional value, SSBs are an easy practical target for sound fiscal policy. WHO has publicly recommended an SSB tax, and many countries, including Mexico, France, Denmark, Hungary, Norway, and the USA, have implemented a tax to generally good effect.

Data from Mexico is particularly promising, the tax reducing consumption by an average of 7.6 per cent a year since its introduction in 2010. In low SES households, this figure reached 17 per cent by the end of 2014. Back home, Australian modelling suggests that a 20 per cent tax could significantly reduce SSB consumption, and there is evidence to suggest that while SSB purchasing would drop, overall drink sales would be unaffected.

This is important for two reasons: first, it makes commercial cooperation significantly more likely, removing an important obstacle to implementation; but secondly, and perhaps more importantly, it means people of low SES wouldn’t simply have to fork out more money in their weekly shop, instead being able to switch to alternative, less sugary drinks.

Australia led the way on taxing tobacco and alcohol. We now have a chance to join other nations around the world, and take responsibility for the enormous impact SSBs have on our health. This alone won’t solve the obesity epidemic, but it is an important tool in the array of public health strategies we need. The AMA quite rightly advocates a ‘whole-of-society’, multi-measure approach to tackling the growing issue of obesity, and a tax on sugary drinks is an important part of this.

The health of our nation depends on us taking affirmative action in this space. The clock is ticking. We can’t afford to wait until it’s too late.

 

Patrick Walker is the 2017 Policy Officer for AMSA Global Health, and was a contributing author to the AMSA policy on Global Food & Nutrition (2016), which, amongst other recommendations, advocated for the implementation of a tax on SSBs.

 Twitter: @patrickjbwalker
Email: patrick.walker@amsa.org.au

 

[Articles] Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study

Despite a high infectious inflammatory burden, the Tsimane, a forager-horticulturalist population of the Bolivian Amazon with few coronary artery disease risk factors, have the lowest reported levels of coronary artery disease of any population recorded to date. These findings suggest that coronary atherosclerosis can be avoided in most people by achieving a lifetime with very low LDL, low blood pressure, low glucose, normal body-mass index, no smoking, and plenty of physical activity. The relative contributions of each are still to be determined.

[Editorial] An ounce of prevention

The Robert Wood Johnson Foundation has released its fourth annual National Health Security Preparedness Index report for the USA, and while there is slow improvement, the results still contain warnings for the state of health security in the USA. The index uses over 200 individual measures across six domains. They range from incident and information management to environmental and occupational health, in order to take a snapshot of the state of preparedness for a health crisis; from an outbreak of expanding infectious diseases, such as Zika or a severe influenza outbreak, to climate-change-fuelled floods and droughts that might displace large numbers of people.

Bertel Sunstrup 24.1.1931 / 22.4.2017

OBITUARY

Bertel Sunstrup   24.1.1931 / 22.4.2017

On the 24th of January 1931, Bert was born in Wondai Queensland. His early days were spent in Gympie.

He went to ‘Shore’ Grammar School in Sydney and graduated MBBS at Sydney University. He did his residency in Launceston and Hobart Hospital before joining Dr Gunson at the Northern Suburbs Medical Clinic in 1958. During this time he (like many GPs) also gave the anaesthetics for the surgeons in both the private and public hospitals. Bert then accepted the Registrar job for the Launceston branch of the Peter Mac Callum Radiotherapy Unit working with Dr Harry Holden.

After a few years he went to England and obtained his ‘Radiotherapy/Oncology’ qualification. Bert returned to the Launceston Hospital to work with Dr Holden and then took over the Radiotherapy/Oncology unit when Dr Holden retired. In 1986 the unit name was changed to the Holman Clinic after its founder in 1928-32.

In his profession Bert witnessed a lot of pain, despair and suffering on a daily basis. He was a dedicated and inspirational clinician who always listened with compassion to his patients being mindful of their difficulties especially in coping with everyday challenges with cancer.

In the 1990s Bert “fought Tooth and Nail” to stop the bureaucrats from transferring the Radiotherapy/Oncology Unit to Hobart. He was steadfastly determined and presented irrefutable arguments that we must continue to treat the patients with all forms of cancers in the North of Tasmania. Were it not for him there would be no clinic in the North. Thankfully the Government agreed to keep the Holman Clinic at the Launceston General Hospital

In 1983 Bert purchased a farm in Pipers Brook and started a vineyard with the help of his wife Anne, her sister Jill and son Christopher. His wine ‘Dalrymple’ soon became well received and they won many medals at the wine shows.

Bert’s other significant interest was skiing. When he returned to Tasmania he married Anne, a registered nurse, had three children. They built their own shack in the Ben Lomond Ski Village. He was a wonderfully entertaining, witty and generous man who had some great parties in their shack. Bert and Anne soon joined the Ben Lomond Ski Patrol and he was promoted from Patrol Doctor to President and eventually to Life Member. Once again it was his infectious energy and enthusiasm that encouraged many to join the patrol and keep the skiers safe and, if injured, to provide them with the correct treatment before they left the mountain.

I loved talking with Bert we shared the same values and had similar aspirations and concerns. He was better informed than I in history and would constantly come up with some interesting trivia.

All past, present and future patients in the North of Tasmania and in particular the Launceston General Hospital are indebted to this friendly, unassuming and dedicated man.

I am certain that his children; Katrina, Ingrid and Christopher as well as his medical colleagues will keep his spirit and legacy alive.

Professor Berni Einoder   A.M.
Director of Surgery at LGH 1984 to 2014

[Comment] Offline: The new neglected (non-tropical) diseases

Neglected tropical diseases (NTDs) are no longer neglected, according to the WHO. “Record-breaking progress” over the past decade has brought diseases such as African trypanosomiasis and lymphatic filariasis “to their knees”. The campaign to defeat NTDs has been “one of the most effective global partnerships in modern public health”, says WHO Director-General Margaret Chan. WHO calls these successes “a rags-to-riches story”. So if NTDs are no longer neglected, what are today’s neglected diseases? One answer must be the non-communicable diseases (NCDs).